Expression of FOXA1 after neoadjuvant chemotherapy, a forkhead family transcription factor, has been found to be significantly related with distant disease-free survival of stage II or III ER+ HER2- BC patients treated with anthracycline/taxane neoadjuvant chemotherapy (Kawase et al., 2015). The gene discussed is ERBB2; the disease is breast cancer.